62 related articles for article (PubMed ID: 8653690)
1. Modulation of p53 expression by human recombinant interferon-alpha2a correlates with abrogation of cisplatin resistance in a human melanoma cell line.
Davol PA; Goulette FA; Frackelton AR; Darnowski JW
Cancer Res; 1996 Jun; 56(11):2522-6. PubMed ID: 8653690
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
3. Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha.
Mecchia M; Matarrese P; Malorni W; D'Agostino G; Sestili P; Santini SM; Gauzzi MC; Venditti M; Mazzocchi A; Parmiani G; Belardelli F; Ferrantini M
Gene Ther; 2000 Jan; 7(2):167-79. PubMed ID: 10673721
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
[TBL] [Abstract][Full Text] [Related]
6. The p53-stabilizing compound, CP-31398, does not enhance chemosensitivity in human melanoma cells.
Luu Y; Li G
Anticancer Res; 2003; 23(1A):99-105. PubMed ID: 12680200
[TBL] [Abstract][Full Text] [Related]
7. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
[TBL] [Abstract][Full Text] [Related]
8. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
9. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis.
Ho CK; Li G
Br J Dermatol; 2005 Nov; 153(5):900-10. PubMed ID: 16225598
[TBL] [Abstract][Full Text] [Related]
11. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
12. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
13. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.
Husain A; Yan XJ; Rosales N; Aghajanian C; Schwartz GK; Spriggs DR
Clin Cancer Res; 1997 Nov; 3(11):2089-97. PubMed ID: 9815601
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
15. Effect of UV-irradiation on cell cycle, viability and the expression of p53, gadd153 and gadd45 genes in normal and HPV-immortalized human oral keratinocytes.
Gujuluva CN; Baek JH; Shin KH; Cherrick HM; Park NH
Oncogene; 1994 Jul; 9(7):1819-27. PubMed ID: 8208528
[TBL] [Abstract][Full Text] [Related]
16. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
17. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.
Satyamoorthy K; Chehab NH; Waterman MJ; Lien MC; El-Deiry WS; Herlyn M; Halazonetis TD
Cell Growth Differ; 2000 Sep; 11(9):467-74. PubMed ID: 11007451
[TBL] [Abstract][Full Text] [Related]
18. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
Siddik ZH; Mims B; Lozano G; Thai G
Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
[TBL] [Abstract][Full Text] [Related]
19. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells.
Jiang H; Lin J; Su ZZ; Herlyn M; Kerbel RS; Weissman BE; Welch DR; Fisher PB
Oncogene; 1995 May; 10(9):1855-64. PubMed ID: 7753561
[TBL] [Abstract][Full Text] [Related]
20. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
Fan S; Smith ML; Rivet DJ; Duba D; Zhan Q; Kohn KW; Fornace AJ; O'Connor PM
Cancer Res; 1995 Apr; 55(8):1649-54. PubMed ID: 7712469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
